Valbenazine and its active metabolite ([+]-α-HTBZ) demonstrate approximate proportional increases for the area under the plasma concentration versus time curve (AUC) and maximum plasma concentration (Cmax) after single oral doses from 40 mg to 300 mg (i.e., 50% to 375% of the recommended treatment dose).
Absorption
INGREZZA
Following oral administration of INGREZZA, the time to reach maximum valbenazine plasma concentration (tmax) ranges from 0.5 to 1.0 hours. Valbenazine reaches steady state plasma concentrations within 1 week. The absolute oral bioavailability of valbenazine is approximately 49%. [+]-α-HTBZ gradually forms and reaches Cmax 4 to 8 hours after administration of INGREZZA.
INGREZZA SPRINKLE
Following administration of 80 mg INGREZZA SPRINKLE orally as sprinkle on applesauce, the geometric mean peak plasma concentration (Cmax) of valbenazine was 512 ng/mL, area under the plasma concentration-time curve (AUCinf) was 5,600 ng*hr/mL and the median time to reach Cmax (Tmax) was 1.5 hours. For the [+]-α-HTBZ metabolite, the geometric mean Cmax was 23 ng/mL, AUCinf was 739 ng*hr/mL and the median Tmax was 6 hours.
Following oral administration of 80 mg INGREZZA, the geometric mean Cmax, AUCinf and median Tmax of valbenazine were 744 ng/mL, 6,419 ng*hr/mL and 0.5 hour, respectively. For the [+]-α-HTBZ metabolite, the geometric mean Cmax was 26 ng/mL, AUCinf was 859 ng*hr/mL and the median Tmax was 6 hours.
When 80 mg INGREZZA SPRINKLE capsules were swallowed whole with water, the geometric mean valbenazine Cmax, AUCinf and median Tmax were 685 ng/mL, 5,981 ng*hr/mL and 1 hour, respectively. For the [+]-α-HTBZ metabolite, the geometric mean Cmax was 23 ng/mL, AUCinf was 772 ng*hr/mL and the median Tmax was 6 hours.
Effect of Food
INGREZZA
Ingestion of a high-fat meal decreases valbenazine Cmax by approximately 47% and AUC by approximately 13%. [+]-α-HTBZ Cmax and AUC are unaffected.
INGREZZA SPRINKLE
Ingestion of a high-fat meal decreases valbenazine Cmax by approximately 15% and did not have an appreciable effect on AUC. [+]-α-HTBZ Cmax and AUC are unaffected.
Distribution
The plasma protein binding of valbenazine and [+]-α-HTBZ are greater than 99% and approximately 64%, respectively. The mean steady state volume of distribution of valbenazine is 92 L.
Nonclinical data in Long-Evans rats show that valbenazine can bind to melanin-containing structures of the eye such as the uveal tract. The relevance of this observation to clinical use of INGREZZA or INGREZZA SPRINKLE is unknown.
Elimination
Valbenazine has a mean total plasma systemic clearance value of 7.2 L/hr. Valbenazine and [+]-α-HTBZ have half-lives of 15 to 22 hours.
Metabolism
Valbenazine is extensively metabolized after oral administration by hydrolysis of the valine ester to form the active metabolite ([+]-α-HTBZ) and by oxidative metabolism, primarily by CYP3A4/5, to form mono-oxidized valbenazine and other minor metabolites. [+]-α-HTBZ appears to be further metabolized in part by CYP2D6.
Excretion
Following the administration of a single 50-mg oral dose of radiolabeled C-valbenazine (i.e., ~63% of the recommended treatment dose), approximately 60% and 30% of the administered radioactivity was recovered in the urine and feces, respectively. Less than 2% was excreted as unchanged valbenazine or [+]-α-HTBZ in either urine or feces.
Specific Populations
Exposures of valbenazine in patients with hepatic and severe renal impairment are summarized in Figure 1.
Figure 1:
Effects of Hepatic and Severe Renal Impairment on Valbenazine Pharmacokinetics
Figure 1 (Valbenazine 02)
AUCinf=area under the plasma concentration versus time curve from 0 hours extrapolated to infinity
[+]-α-HTBZ=[+]-α-dihydrotetrabenazine (active metabolite)
Drug Interaction Studies
In Vivo Drug Interactions
The effects of paroxetine, ketoconazole and rifampin on the exposure of valbenazine are summarized in Figure 2.
Figure 2:
Effects of Strong CYP2D6 and CYP3A4 Inhibitors and CYP3A4 Inducers on Valbenazine Pharmacokinetics
Figure 2 (Valbenazine 03)
AUCinf=area under the plasma concentration versus time curve from 0 hours extrapolated to infinity
[+]-α-HTBZ=[+]-α-dihydrotetrabenazine (active metabolite)
The effects of valbenazine on the exposure of other coadministered drugs are summarized in Figure 3.
Figure 3:
Effects of Valbenazine on Pharmacokinetics of Other Drugs
Figure 3 (Valbenazine 04)
AUCinf=area under the plasma concentration versus time curve from 0 hours extrapolated to infinity
In Vitro Drug Interactions
The results of in vitro studies suggest that valbenazine and [+]-α-HTBZ are unlikely to inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2E1 or CYP3A4/5, or induce CYP1A2, CYP2B6 or CYP3A4/5 at clinically relevant concentrations.
The results of in vitro studies suggest that valbenazine and [+]-α-HTBZ are unlikely to inhibit the transporters (BCRP, OAT1, OAT3, OCT2, OATP1B1, or OATP1B3) at clinically relevant concentrations.